Recurrent Osteosarcoma Recruiting Phase 1 / 2 Trials for Azacitidine (DB00928)

Also known as: Osteosarcoma recurrent / Osteogenic sarcoma recurrent

IndicationStatusPhase
DBCOND0028757 (Recurrent Osteosarcoma)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03628209Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable OsteosarcomaTreatment